Avenge Bio

Avenge Bio was founded by an experienced team of proven biotech executives to develop transformative therapeutics which can potentially eradicate intractable solid tumors. Avenge Bio is developing our proprietary, allogeneic LOCOcyteTM platform for precision delivery of cytokines and other highly potent immunomodulatory molecules for a controlled period of time. Through this approach we are able to generate robust, local and systemic anti-tumor immune responses, without the toxicities associated with traditional immunotherapies. The LOCOcyteTM platform was developed from extensive research and experience of Dr. Omid Veiseh at Rice University and supported by Longitude Capital, CAM Capital, Perceptive Xontogeny, Rock Springs, Pappas Capital, and other leading healthcare investors. Together we are using the strength and efficiency of our platform to create a broad pipeline of therapeutics that target a wide range of difficult to treat solid tumors.

Avenge Bio completes first dose cohort in AVB-001 Phase I/II trial

Avenge Bio Developing Cell Generated Immunotherapies to Eradicate Solid Tumors

Avenge Bio CEO and Key Executive Team

Sara Kalb - Research Associate - Avenge Bio

avengebio (@AvengeBio) / X

avengebio (@AvengeBio) / X

Commercialization Highlights, Office of Technology Transfer, Office of Research

Jeep Avenger Bio-Hybrid: conhecemos o motor híbrido do novo SUV nacional

MartialArts Reigns (on WEBCOMICS, link in bio, C.0.D.E of Starter Perk

Douglas Carlson on LinkedIn: Avenge Bio Announces Dosing of First Patient in Phase 1/2 Clinical Trial…

Michael Heffernan